Generate Biomedicines Inc. Common Stock (GENB)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Generate Biomedicines with Graham's insistence on evidence and Buffett's preference for understandable, cash-generative businesses. Generate uses machine learning to design protein therapeutics, an ambitious field, but the financial record is thin and unproven. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $6.3M and net loss was $67.3M, with diluted EPS of -$0.52. That compares poorly with fiscal Q2 2025, the quarter ended 2025-06-30, when revenue was $10.1M and net loss was $52.4M. Fiscal Q1 2026, ended 2026-03-31, had $7.2M of revenue and a $61.4M loss, while fiscal Q1 2025, ended 2025-03-31, had $8.8M of revenue and a $41.7M loss. Revenue is falling while losses widen, never a comforting trend. At the 2026-10-13 close, the price was $12.26 and market cap was $1.6B. FairStock calculations show a P/E of -5.84, so trailing earnings offer no anchor, and a P/B of 3.44, so investors pay a premium to book value for a business with ROE of -81.72% and ROCE of -34.63%. Free cash flow was -$245.9M, with a FairStock FCF yield of -15.6%, meaning cash is being consumed. FairStock's Piotroski F-Score is 1/9. On the positive side, debt to equity is only 0.14, and the Altman Z-Score of 7.40 suggests low near-term balance-sheet distress risk. Still, the moat is unproven. Value rests on future drug candidates like GB-0895 and GB-4362, not current profits. The FairStock Score is 20/100, and the computed Lynch category is none because there are only zero years of filed results and three are needed. At this price, I see no margin of safety.

In plain English: Generate Biomedicines uses machine learning to discover protein-based medicines. It is not profitable, its revenue is shrinking, and it spends a lot of cash. At $12.26 on 2026-10-13, the price looks expensive compared with the company's current losses and weak financial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer